Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight

Abstract Purpose An increase of IGF-1 has been reported during therapy with dopamine agonists (DA) for prolactinomas; in such cases a correct diagnosis is pivotal to avoid an unnecessary reduction or withdrawal of DA, which are needed to maintain normal prolactin levels. This study was aimed to meas...

Celý popis

Podrobná bibliografie

Hlavní autoři:	S. Caprio, T. Pilli, S. Cantara, F. Sestini, C. Fioravanti, C. Ciuoli, C. Dalmiglio, A. Corbo, M. G. Castagna
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2024-06-01
Edice:	BMC Endocrine Disorders
Témata:	Prolactinoma Dopamine-agonists IGF-1 Body mass index
On-line přístup:	https://doi.org/10.1186/s12902-024-01622-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!